EP2145902A3 - Tyrosine phosphorylation sites and antibodies specific for them - Google Patents

Tyrosine phosphorylation sites and antibodies specific for them Download PDF

Info

Publication number
EP2145902A3
EP2145902A3 EP09170140A EP09170140A EP2145902A3 EP 2145902 A3 EP2145902 A3 EP 2145902A3 EP 09170140 A EP09170140 A EP 09170140A EP 09170140 A EP09170140 A EP 09170140A EP 2145902 A3 EP2145902 A3 EP 2145902A3
Authority
EP
European Patent Office
Prior art keywords
phosphorylation sites
antibodies specific
tyrosine phosphorylation
peptides
phosphorylation site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09170140A
Other languages
German (de)
French (fr)
Other versions
EP2145902A2 (en
Inventor
Peter Hornbeck
Ailan Guo
Ting-Lei Gu
Albrecht Moritz
Charles Farnsworth
Matthew Stokes
Jian Yu
Erik Spek
Anthony Possemato
Valerie Goss
Jeffrey Mtchell
John Rush
Yu Li
Klarisa Rikova
Jessica Cherry
Corinne Michaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/744,753 external-priority patent/US20080014598A1/en
Application filed by Individual filed Critical Individual
Publication of EP2145902A2 publication Critical patent/EP2145902A2/en
Publication of EP2145902A3 publication Critical patent/EP2145902A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention discloses 482 novel phosphorylation sites identified in carcinoma and/or leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.
EP09170140A 2007-04-19 2008-04-18 Tyrosine phosphorylation sites and antibodies specific for them Withdrawn EP2145902A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92525307P 2007-04-19 2007-04-19
US11/744,753 US20080014598A1 (en) 2006-07-13 2007-05-04 Phospho-specific antibodies to pi3k regulatory subunit and uses thereof
US99962807P 2007-10-19 2007-10-19
EP08154839A EP1983002A3 (en) 2007-04-19 2008-04-18 Tyrosine phosphorylation sites and antibodies specific for them

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP08154839.8 Division 2008-04-18
EP08154839A Division EP1983002A3 (en) 2007-04-19 2008-04-18 Tyrosine phosphorylation sites and antibodies specific for them

Publications (2)

Publication Number Publication Date
EP2145902A2 EP2145902A2 (en) 2010-01-20
EP2145902A3 true EP2145902A3 (en) 2010-09-29

Family

ID=39671811

Family Applications (2)

Application Number Title Priority Date Filing Date
EP09170140A Withdrawn EP2145902A3 (en) 2007-04-19 2008-04-18 Tyrosine phosphorylation sites and antibodies specific for them
EP08154839A Withdrawn EP1983002A3 (en) 2007-04-19 2008-04-18 Tyrosine phosphorylation sites and antibodies specific for them

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP08154839A Withdrawn EP1983002A3 (en) 2007-04-19 2008-04-18 Tyrosine phosphorylation sites and antibodies specific for them

Country Status (1)

Country Link
EP (2) EP2145902A3 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212228B2 (en) 2005-11-24 2015-12-15 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9512232B2 (en) 2012-05-09 2016-12-06 Ganymed Pharmaceuticals Ag Antibodies against Claudin 18.2 useful in cancer diagnosis
US9775785B2 (en) 2004-05-18 2017-10-03 Ganymed Pharmaceuticals Ag Antibody to genetic products differentially expressed in tumors and the use thereof
US10414824B2 (en) 2002-11-22 2019-09-17 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
EP2350320A4 (en) 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHODS AND SYSTEMS FOR USING EXOSOMES TO DETERMINE PHENOTYPES
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
KR20130043104A (en) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 Circulating biomarkers for disease
EP2573565A1 (en) 2011-09-23 2013-03-27 Gerhard Matthias Kresbach Immune detection method for common epitopes of two or more analytes in samples of complex compositions, device, and kit for enabling said immune detection method
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
IL282953B2 (en) 2012-11-13 2026-02-01 Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh Agents for treatment of claudin expressing cancer diseases
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2019030311A1 (en) * 2017-08-09 2019-02-14 Pamgene Bv Method for predicting the response of non-small-cell lung carcinoma patients to a medicament

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070899A2 (en) * 2002-02-20 2003-08-28 Cell Signaling Technology, Inc. Phospho-specific antibodies to flt3 and uses thereof
WO2007019273A2 (en) * 2005-08-04 2007-02-15 Albert Einstein College Of Medicine Of Yeshiva University Phosphorylation of tau by abl

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
NL7905543A (en) 1979-07-17 1981-01-20 Philips Nv MEMORY WITH CURRENT CONTROLLED SERIES / PARALLEL CONVERSION OF MAGNETIC BELL DOMAINS.
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
CH652145A5 (en) 1982-01-22 1985-10-31 Sandoz Ag METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE.
DE3307869A1 (en) 1983-03-05 1984-09-06 Dragoco Gerberding & Co Gmbh, 3450 Holzminden METHYL-SUBSTITUTED 1 - ((3-METHYLTHIO) -1-OXO-BUTYL) -CYCLOHEX-2-ENE, METHOD FOR THE PRODUCTION AND USE THEREOF AS A SMELLING AND FLAVORING SUBSTANCE
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
EP0335476A3 (en) 1984-02-08 1989-12-13 Cetus Corporation Recombinant methods for the production of ricin a, ricin b, ricin or diphtheria toxin (dt)a or ab' fragment, suitable hosts and vectors therefor, and conjugates comprising ricin toxin a chain or diphtheria toxin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5092885A (en) 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5004692A (en) 1987-12-15 1991-04-02 Protein Design Labs, Inc. Cloning and expression of phosopholipase C genes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
KR0162259B1 (en) 1989-12-05 1998-12-01 아미 펙터 Chimeric Antibodies for Detection and Treatment of Infectious and Inflammatory Lesions
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE130517T1 (en) 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd INTRAVASCULAR EMBOLIZING AGENT CONTAINING A SUBSTANCE INHIBITING ANGIOGENESIS.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU1411992A (en) 1991-01-15 1992-08-27 Robert A Bok A composition containing a tetracycline and use for inhibiting angiogenesis
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
US6027725A (en) 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
DE69233528T2 (en) 1991-11-25 2006-03-16 Enzon, Inc. Process for the preparation of multivalent antigen-binding proteins
JPH07503132A (en) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド Transgenic non-human animals capable of producing xenoantibodies
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
ES2201097T3 (en) 1994-01-31 2004-03-16 Trustees Of Boston University POLYCLONAL ANTIBODIES LIBRARIES.
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
DE69505991T2 (en) 1994-07-13 1999-04-08 Sca Hygiene Paper Ab, Goeteborg/Gotenburg METHOD FOR PRODUCING A NONWOVEN FABRIC
US5675063A (en) 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
EP0857210B1 (en) 1995-10-23 2003-09-03 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US6465431B1 (en) 1999-11-17 2002-10-15 Boston Life Sciences, Inc. Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis
SK163598A3 (en) 1996-05-31 1999-06-11 Scripps Research Inst Methods and compositions useful for inhibition of angiogenesis
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6475784B1 (en) 1997-11-14 2002-11-05 Valentis, Inc. Inhibition of angiogenesis by delivery of nucleic acids encoding anti-angiogenic polypeptides
JP4418105B2 (en) 1997-12-26 2010-02-17 持田製薬株式会社 Angiogenesis inhibitors containing dienogest as an active ingredient
AU3980499A (en) 1998-05-11 1999-11-29 Endowment for Research in Human Biology, Inc., The Use of neomycin for treating angiogenesis-related diseases
US6413513B1 (en) 1998-05-22 2002-07-02 Entremed, Inc. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
US6395718B1 (en) 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
US6500431B1 (en) 1998-07-13 2002-12-31 University Of Southern California Inhibitors of angiogenesis and tumor growth
WO2000003726A1 (en) 1998-07-14 2000-01-27 Bristol-Myers Squibb Company Lysine binding fragments of angiostatin
WO2000010507A2 (en) 1998-08-21 2000-03-02 The Children's Medical Center Corporation Use of melanin for inhibition of angiogenesis and macular degeneration
US7198896B2 (en) 1998-09-04 2007-04-03 Cell Signaling Technology, Inc. Immunoaffinity isolation of modified peptides from complex mixtures
EP1242352A2 (en) 1999-12-23 2002-09-25 University Of Georgia Research Foundation, Inc. Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
JP2003528632A (en) 2000-03-31 2003-09-30 インスティティ・パスツール Peptide inhibiting vascular endothelial growth factor (VEGF) -mediated angiogenesis, polynucleotide encoding the peptide and methods of use
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
AU2002323139A1 (en) 2001-08-14 2003-03-03 President And Fellows Of Harvard College Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry
JP2005538049A (en) 2002-05-01 2005-12-15 トレリス バイオサイエンス、インク． Dual or multi-dimensional targeting and its use
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
US20040091490A1 (en) 2002-08-28 2004-05-13 Robert Johnson Stable pH optimized formulation of a modified antibody
JP2006516636A (en) 2003-01-30 2006-07-06 メディミューン，インコーポレーテッド Anti-integrin αvβ3 antibody preparation and use thereof
PT1610820E (en) 2003-04-04 2010-12-16 Novartis Ag High concentration antibody and protein formulations
WO2007027867A2 (en) * 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US20090203034A1 (en) * 2006-05-12 2009-08-13 Ailan Guo Reagents for the detection of tyrosine phosphorylation in brain ischemia signaling pathways
US7999080B2 (en) * 2006-07-13 2011-08-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in signaling pathways
WO2008013953A2 (en) * 2006-07-27 2008-01-31 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
US20100129929A1 (en) * 2006-07-27 2010-05-27 Roberto Polakewicz Tyrosine Phosphorylation Sites
WO2008054597A2 (en) * 2006-09-28 2008-05-08 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070899A2 (en) * 2002-02-20 2003-08-28 Cell Signaling Technology, Inc. Phospho-specific antibodies to flt3 and uses thereof
WO2007019273A2 (en) * 2005-08-04 2007-02-15 Albert Einstein College Of Medicine Of Yeshiva University Phosphorylation of tau by abl

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CELL SIGNALING: "phospho tyrosine mouse mab P-tyr-100", 1 March 2005 (2005-03-01), XP002571608, Retrieved from the Internet <URL:http://www.cellsignal.com/pdf/9411.pdf> [retrieved on 20100305] *
DATABASE UniProt 1 March 2005 (2005-03-01), XP002571607, Database accession no. O60292 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10414824B2 (en) 2002-11-22 2019-09-17 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
US9775785B2 (en) 2004-05-18 2017-10-03 Ganymed Pharmaceuticals Ag Antibody to genetic products differentially expressed in tumors and the use thereof
US9212228B2 (en) 2005-11-24 2015-12-15 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9499609B2 (en) 2005-11-24 2016-11-22 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9512232B2 (en) 2012-05-09 2016-12-06 Ganymed Pharmaceuticals Ag Antibodies against Claudin 18.2 useful in cancer diagnosis

Also Published As

Publication number Publication date
EP2145902A2 (en) 2010-01-20
EP1983002A2 (en) 2008-10-22
EP1983002A3 (en) 2009-03-11

Similar Documents

Publication Publication Date Title
EP1983002A3 (en) Tyrosine phosphorylation sites and antibodies specific for them
WO2008013948A3 (en) Tyrosine phosphorylation sites
WO2008073162A3 (en) Lysine acetylation sites
EP2468776A3 (en) Anti-Robo4 antibodies and uses therefor
WO2008054597A3 (en) Tyrosine phosphorylation sites
EP3301117A3 (en) Specific binding proteins and uses thereof
EP2371865A3 (en) Antibodies that bind human protein tyrosine phosphatase beta (HPTP-ß) and uses thereof
EP1983003A3 (en) Tyrosine phosphorylation sites and antibodies specific for them
EP2546261A3 (en) New compositions, methods and use
EP1972639A3 (en) Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP2889312A3 (en) Treatment of autoimmune disease by modulating Annexin-1 (lipocortin 1)
DE602005026789D1 (en) LE
EP2485047A3 (en) Methods and marker combinations for screening for predisposition to lung cancer
IL197831A (en) Human antibodies that bind cxcr4, compositions comprising the same and uses thereof
EP2388271A3 (en) Human Antibodies and Proteins
WO2008150485A3 (en) Erbb2 binding proteins and use thereof
EP2366716A3 (en) Combinatorial therapy involving alpha5beta1 antagonists
EP2631248A3 (en) Treatment of tumors using specific anti-L1 antibody
EP2322931A3 (en) Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
WO2008104804A3 (en) Proteins
EP3210625A3 (en) Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica)
WO2011041319A8 (en) Specific binding proteins and uses thereof
WO2008013934A3 (en) Tyrosine phosphorylation sites
WO2009055074A8 (en) Erbb2 binding proteins and use thereof
GB2449044A (en) Cytotoxicity mediation of cells evidencing surface expression of cd63

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1983002

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101103